OSE Immunotherapeutics Aktie - OSE

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

6,67

Gebot

6,65

Fragen

6,77

Volumen

686.111

6,53 Tagesbereich 7,07

4,41 52-Wochen-Bereich 11,58

Marktkapitalisierung

145,191M

Handelsende

5,79

Handelsbeginn

6,90

Letzte Trade

100

6.67

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

109.520

Ausgegebene Aktien

21.767.777

Dividendenrendite

Kurs-Gewinn-Verhältnis

-6,31

Gewinn pro Aktie (EPS)

-1,06

Erlöse

2,23M

Nettogewinn

-23M

Sektor

Coml Physical, Biologcl Resh

Branche

Coml Physical, Biologcl Resh

Website

www.ose-immuno.com

Hauptsitz

Nantes, Loire-atlantique, Fra

Gegründet

OSE Immunotherapeutics is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker OSE. The last closing price for OSE Immunotherapeutics was 5,79 €. Over the last year, OSE Immunotherapeutics shares have traded in a share price range of 4,41 € to 11,58 €.

OSE Immunotherapeutics currently has 21.767.777 shares in issue. The market capitalisation of OSE Immunotherapeutics is 126,04 € million. OSE Immunotherapeutics has a price to earnings ratio (PE ratio) of -6.31.

OSE Immunotherapeutics et le GERCOR annoncent des premiers résultats cliniques positifs de OSE2101 (Tedopi®) dans l’essai clinique de Phase 2 TEDOPaM dans le cancer du pancréas avancé

OSE Immunotherapeutics et le GERCOR annoncent des premiers résultats cliniques positifs de OSE2101 (Tedopi®) dans l’essai clinique de Phase 2...

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced...

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Informations relatives au nombre total de droits de vote et d’actions composant le capital Informations relatives au nombre total de droits de...

Webinaire post-ECCO d’OSE Immunotherapeutics Lusvertikimab dans le paysage thérapeutique des MICI : Le point de vue des leaders d’opinion

Webinaire post-ECCO d’OSE Immunotherapeutics Lusvertikimab dans le paysage thérapeutique des MICI : Le point de vue des leaders d’opinion...

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on...

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD NANTES, France –...

OSE Immunotherapeutics présente les résultats complets d’induction de l’étude Phase 2 de l’anticorps monoclonal anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO

OSE Immunotherapeutics présente les résultats complets d’induction de l’étude Phase 2 de l’anticorps monoclonal anti-IL-7R Lusvertikimab dans la...

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative...

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO...

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.4	6.37958532695	6.27	7.07	5.75	100104	6.08207456	DE
4	-0.17	-2.48538011696	6.84	7.58	5.75	124530	6.7368078	DE
12	-0.6	-8.25309491059	7.27	7.85	5.75	109520	6.77692684	DE
26	-0.54	-7.48959778086	7.21	11.58	5.75	158708	8.23908656	DE
52	1.54	30.0194931774	5.13	11.58	4.41	169476	7.47492127	DE
156	0.29	4.54545454545	6.38	11.58	2.705	111294	6.32050363	DE
260	3.22	93.3333333333	3.45	15.8	2.705	105418	7.42002589	DE

OSE - Frequently Asked Questions (FAQ)

What is the current OSE Immunotherapeutics share price?

The current share price of OSE Immunotherapeutics is 6,67 €

How many OSE Immunotherapeutics shares are in issue?

OSE Immunotherapeutics has 21.767.777 shares in issue

What is the market cap of OSE Immunotherapeutics?

The market capitalisation of OSE Immunotherapeutics is EUR 126,04M

What is the 1 year trading range for OSE Immunotherapeutics share price?

OSE Immunotherapeutics has traded in the range of 4,41 € to 11,58 € during the past year

What is the PE ratio of OSE Immunotherapeutics?

The price to earnings ratio of OSE Immunotherapeutics is -6,31

What is the cash to sales ratio of OSE Immunotherapeutics?

The cash to sales ratio of OSE Immunotherapeutics is 65,2

What is the reporting currency for OSE Immunotherapeutics?

OSE Immunotherapeutics reports financial results in EUR

What is the latest annual turnover for OSE Immunotherapeutics?

The latest annual turnover of OSE Immunotherapeutics is EUR 2,23M

What is the latest annual profit for OSE Immunotherapeutics?

The latest annual profit of OSE Immunotherapeutics is EUR -23M

What is the registered address of OSE Immunotherapeutics?

The registered address for OSE Immunotherapeutics is 22 BOULEVARD DE BENONI GOULLIN, NANTES, LOIRE-ATLANTIQUE, 44200

What is the OSE Immunotherapeutics website address?

The website address for OSE Immunotherapeutics is www.ose-immuno.com

Which industry sector does OSE Immunotherapeutics operate in?

OSE Immunotherapeutics operates in the COML PHYSICAL, BIOLOGCL RESH sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
AMPLIAmplitude Surgical	5,95 € (71,97%)	78,31k
ALCYBCybergun	0,0003 € (50,00%)	743,66M
MLSTRStreit Mecanique	11,20 € (40,00%)	7
MLPACPacte Novation	9,70 € (31,97%)	3
ALCABCabasse SA	1,00 € (31,58%)	10,87k
DMSBSDiagnostic Medical Systems	0,005 € (-71,43%)	111,66k
MLCOTCoretech 5	0,0255 € (-50,00%)	660
NICBSNicox SA	0,0125 € (-31,32%)	34,6k
LUDSLucibel DS	0,0005 € (-28,57%)	167,91k
ALBOOBOOSTHEAT	0,0048 € (-27,27%)	1,24M
ALVERVergnet	0,0003 € (0,00%)	320,15M
ATOAtos SE	0,0041 € (10,81%)	293,54M
ALCYBCybergun	0,0003 € (50,00%)	87,58M
BCPBanco Comercial Portugues SA	0,5408 € (3,60%)	30,61M
ALEUPEuroplasma	0,0176 € (-19,27%)	22,65M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

OSE Immunotherapeutics (OSE)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über OSE Immunotherapeutics

OSE Neueste Nachrichten

OSE Immunotherapeutics et le GERCOR annoncent des premiers résultats cliniques positifs de OSE2101 (Tedopi®) dans l’essai clinique de Phase 2 TEDOPaM dans le cancer du pancréas avancé

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Webinaire post-ECCO d’OSE Immunotherapeutics Lusvertikimab dans le paysage thérapeutique des MICI : Le point de vue des leaders d’opinion

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

OSE Immunotherapeutics présente les résultats complets d’induction de l’étude Phase 2 de l’anticorps monoclonal anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO

OSE Immunotherapeutics et le GERCOR annoncent des premiers résultats cliniques positifs de OSE2101 (Tedopi®) dans l’essai clinique de Phase 2 TEDOPaM dans le cancer du pancréas avancé

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer

Informations relatives au nombre total de droits de vote et d’actions composant le capital

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

Webinaire post-ECCO d’OSE Immunotherapeutics Lusvertikimab dans le paysage thérapeutique des MICI : Le point de vue des leaders d’opinion

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

OSE Immunotherapeutics (OSE) Börsenkurse

OSE Immunotherapeutics (OSE)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über OSE Immunotherapeutics

OSE Neueste Nachrichten

OSE Immunotherapeutics et le GERCOR annoncent des premiers résultats cliniques positifs de OSE2101 (Tedopi®) dans l’essai clinique de Phase 2 TEDOPaM dans le cancer du pancréas avancé

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Webinaire post-ECCO d’OSE Immunotherapeutics Lusvertikimab dans le paysage thérapeutique des MICI : Le point de vue des leaders d’opinion

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

OSE Immunotherapeutics présente les résultats complets d’induction de l’étude Phase 2 de l’anticorps monoclonal anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO

OSE Immunotherapeutics et le GERCOR annoncent des premiers résultats cliniques positifs de OSE2101 (Tedopi®) dans l’essai clinique de Phase 2 TEDOPaM dans le cancer du pancréas avancé

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer

Informations relatives au nombre total de droits de vote et d’actions composant le capital

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

Webinaire post-ECCO d’OSE Immunotherapeutics Lusvertikimab dans le paysage thérapeutique des MICI : Le point de vue des leaders d’opinion

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen